BerGenBio: Promising Data Highlighting Bemcentinib’s Potential to Improve Efficacy of Checkpoint Inhibitors to be Presented at AACR Annual Meeting

March 14, 2018

Responsive image

BERGEN, Norway, March 15, 2017 /PRNewswire/ – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that promising preclinical data with BerGenBio’s lead AXL inhibitor bemcentinib…

Category: Precious Metals